Literature DB >> 26378885

Contrasting actions of a convulsant barbiturate and its anticonvulsant enantiomer on the α1 β3 γ2L GABAA receptor account for their in vivo effects.

Rooma Desai1, Pavel Y Savechenkov2, Dorota Zolkowska3, Ri Le Ge1, Michael A Rogawski3, Karol S Bruzik2, Stuart A Forman1, Douglas E Raines1, Keith W Miller1,4.   

Abstract

KEY POINTS: Most barbiturates are anaesthetics but unexpectedly a few are convulsants whose mechanism of action is poorly understood. We synthesized and characterized a novel pair of chiral barbiturates that are capable of photolabelling their binding sites on GABAA receptors. In mice the S-enantiomer is a convulsant, but the R-enantiomer is an anticonvulsant. The convulsant S-enantiomer binds solely at an inhibitory site. It is both an open state inhibitor and a resting state inhibitor. Its action is pH independent, suggesting the pyrimidine ring plays little part in binding. The inhibitory site is not enantioselective because the R-enantiomer inhibits with equal affinity. In contrast, only the anticonvulsant R-enantiomer binds to the enhancing site on open channels, causing them to stay open longer. The enhancing site is enantioselective. The in vivo actions of the convulsant S-enantiomer are accounted for by its interactions with GABAA receptors. ABSTRACT: Most barbiturates are anaesthetics but a few unexpectedly are convulsants. We recently located the anaesthetic sites on GABAA receptors (GABAA Rs) by photolabelling with an anaesthetic barbiturate. To apply the same strategy to locate the convulsant sites requires the creation and mechanistic characterization of a suitable agent. We synthesized enantiomers of a novel, photoactivable barbiturate, 1-methyl-5-propyly-5-(m-trifluoromethyldiazirinyl) phenyl barbituric acid (mTFD-MPPB). In mice, S-mTFD-MPPB acted as a convulsant, whereas R-mTFD-MPPB acted as an anticonvulsant. Using patch clamp electrophysiology and fast solution exchange on recombinant human α1 β3 γ2L GABAA Rs expressed in HEK cells, we found that S-mTFD-MPPB inhibited GABA-induced currents, whereas R-mTFD-MPPB enhanced them. S-mTFD-MPPB caused inhibition by binding to either of two inhibitory sites on open channels with bimolecular kinetics. It also inhibited closed, resting state receptors at similar concentrations, decreasing the channel opening rate and shifting the GABA concentration-response curve to the right. R-mTFD-MPPB, like most anaesthetics, enhanced receptor gating by rapidly binding to allosteric sites on open channels, initiating a rate-limiting conformation change to stabilized open channel states. These states had slower closing rates, thus shifting the GABA concentration-response curve to the left. Under conditions when most GABAA Rs were open, an inhibitory action of R-mTFD-MPPB was revealed that had a similar IC50 to that of S-mTFD-MPPB. Thus, the inhibitory sites are not enantioselective, and the convulsant action of S-mTFD-MPPB results from its negligible affinity for the enhancing, anaesthetic sites. Interactions with these two classes of barbiturate binding sites on GABAA Rs underlie the enantiomers' different pharmacological activities in mice.
© 2015 The Authors. The Journal of Physiology © 2015 The Physiological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26378885      PMCID: PMC4650410          DOI: 10.1113/JP270971

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  69 in total

1.  The α1K276E startle disease mutation reveals multiple intermediate states in the gating of glycine receptors.

Authors:  Remigijus Lape; Andrew J R Plested; Mirko Moroni; David Colquhoun; Lucia G Sivilotti
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

2.  Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog.

Authors:  Guo-Dong Li; David C Chiara; Gregory W Sawyer; S Shaukat Husain; Richard W Olsen; Jonathan B Cohen
Journal:  J Neurosci       Date:  2006-11-08       Impact factor: 6.167

Review 3.  Inhibitory ligand-gated ion channels as substrates for general anesthetic actions.

Authors:  A Zeller; R Jurd; S Lambert; M Arras; B Drexler; C Grashoff; B Antkowiak; U Rudolph
Journal:  Handb Exp Pharmacol       Date:  2008

4.  Seizure protection by intrapulmonary delivery of propofol hemisuccinate.

Authors:  Ashish Dhir; Dorota Zolkowska; Randall B Murphy; Michael A Rogawski
Journal:  J Pharmacol Exp Ther       Date:  2010-09-13       Impact factor: 4.030

5.  Modes and models of GABA(A) receptor gating.

Authors:  Gareth M C Lema; Anthony Auerbach
Journal:  J Physiol       Date:  2006-02-02       Impact factor: 5.182

Review 6.  Anesthetic sites and allosteric mechanisms of action on Cys-loop ligand-gated ion channels.

Authors:  Stuart A Forman; Keith W Miller
Journal:  Can J Anaesth       Date:  2011-01-07       Impact factor: 5.063

7.  Gamma-amino butyric acid type A receptor mutations at beta2N265 alter etomidate efficacy while preserving basal and agonist-dependent activity.

Authors:  Rooma Desai; Dirk Ruesch; Stuart A Forman
Journal:  Anesthesiology       Date:  2009-10       Impact factor: 7.892

Review 8.  GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation.

Authors:  Richard W Olsen; Guo-Dong Li
Journal:  Can J Anaesth       Date:  2010-12-31       Impact factor: 5.063

9.  Pentobarbital produces activation and block of {alpha}1{beta}2{gamma}2S GABAA receptors in rapidly perfused whole cells and membrane patches: divergent results can be explained by pharmacokinetics.

Authors:  Kevin J Gingrich; Paul M Burkat; William A Roberts
Journal:  J Gen Physiol       Date:  2009-02       Impact factor: 4.086

10.  Detection and trapping of intermediate states priming nicotinic receptor channel opening.

Authors:  Nuriya Mukhtasimova; Won Yong Lee; Hai-Long Wang; Steven M Sine
Journal:  Nature       Date:  2009-04-01       Impact factor: 49.962

View more
  7 in total

Review 1.  Comparison of αβδ and αβγ GABAA receptors: Allosteric modulation and identification of subunit arrangement by site-selective general anesthetics.

Authors:  Hua-Jun Feng; Stuart A Forman
Journal:  Pharmacol Res       Date:  2017-12-30       Impact factor: 7.658

2.  Enantiomeric barbiturates bind distinct inter- and intrasubunit binding sites in a nicotinic acetylcholine receptor (nAChR).

Authors:  Zhiyi Yu; Jonathan B Cohen
Journal:  J Biol Chem       Date:  2017-09-06       Impact factor: 5.157

3.  Identifying Drugs that Bind Selectively to Intersubunit General Anesthetic Sites in the α1β3γ2 GABAAR Transmembrane Domain.

Authors:  Selwyn S Jayakar; Xiaojuan Zhou; David C Chiara; Carlos Jarava-Barrera; Pavel Y Savechenkov; Karol S Bruzik; Mariola Tortosa; Keith W Miller; Jonathan B Cohen
Journal:  Mol Pharmacol       Date:  2019-04-05       Impact factor: 4.436

4.  High-throughput Screening in Larval Zebrafish Identifies Novel Potent Sedative-hypnotics.

Authors:  Xiaoxuan Yang; Youssef Jounaidi; Jennifer B Dai; Francisco Marte-Oquendo; Elizabeth S Halpin; Lauren E Brown; Richard Trilles; Wenqing Xu; Renee Daigle; Buwei Yu; Scott E Schaus; John A Porco; Stuart A Forman
Journal:  Anesthesiology       Date:  2018-09       Impact factor: 7.892

5.  Novel positive allosteric modulators of GABAA receptors with anesthetic activity.

Authors:  Maria C Maldifassi; Roland Baur; David Pierce; Anahita Nourmahnad; Stuart A Forman; Erwin Sigel
Journal:  Sci Rep       Date:  2016-05-20       Impact factor: 4.379

6.  Correction for Inhibition Leads to an Allosteric Co-Agonist Model for Pentobarbital Modulation and Activation of α1β3γ2L GABAA Receptors.

Authors:  Alexis M Ziemba; Stuart A Forman
Journal:  PLoS One       Date:  2016-04-25       Impact factor: 3.240

7.  Cryo-EM structure of the human α1β3γ2 GABAA receptor in a lipid bilayer.

Authors:  Duncan Laverty; Rooma Desai; Tomasz Uchański; Simonas Masiulis; Wojciech J Stec; Tomas Malinauskas; Jasenko Zivanov; Els Pardon; Jan Steyaert; Keith W Miller; A Radu Aricescu
Journal:  Nature       Date:  2019-01-02       Impact factor: 49.962

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.